TY - JOUR
T1 - Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
AU - Sancho, Juan Manuel
AU - Orfao, Alberto
AU - Quijano, Sandra
AU - García, Olga
AU - Panizo, Carlos
AU - Pérez-Ceballos, Elena
AU - Deben, Guillermo
AU - Salar, Antonio
AU - González-Barca, Eva
AU - Alonso, Natalia
AU - García-Vela, Jose Antonio
AU - Capote, Javier
AU - Peñalver, Francisco Javier
AU - Provencio, Mariano
AU - Arias, Jesús
AU - Plaza, Josefa
AU - Caballero, Dolores
AU - Morado, Marta
AU - Feliu, Evarist
AU - Ribera, Josep Maria
PY - 2010/10
Y1 - 2010/10
N2 - Background and aim: Flow cytometry (FCM) analysis of cerebrospinal fluid (CSF) is more sensitive than conventional cytology (CC) for diagnosis of lymphomatous meningeosis, but the clinical significance of occult central nervous system (CNS) disease (positive FCM with negative CC) remains unknown. Patients and methods: CSF samples from 105 patients with newly diagnosed aggressive lymphomas at high risk of CNS involvement were prospectively studied by both CC and FCM, and results were correlated with cumulative incidence of CNS relapse and overall survival (OS). Patients were divided into three groups: 1) patients without CNS involvement (CC-/FCM-; n = 83); 2) individuals with occult CNS disease (FCM+/CC-; n = 15); and 3) cases with CNS disease (CC+/FCM+; n = 7). Results: Six cases showed CNS relapse or progression: two in Group 1 (2.4%), two in Group 2 (13%) and two in Group 3 (28.5%) (Group 2 vs. 1, P = 0.04; Group 3 vs. 1, P < 0.001). Patients from Groups 2 (P = 0.05) and 3 (P < 0.001) also showed a higher cumulative incidence of CNS relapse than those from Group 1. Significant differences were observed in OS between FCM-/CC- and FCM+/CC+ cases (P = 0.02), while patients with occult CNS disease (FCM+/CC-) displayed intermediate OS rates, although differences did not reach statistical significance. Conclusions: The presence of occult CNS involvement at diagnosis in patients with NHL at high risk of CNS disease is associated with a higher probability of CNS relapse.
AB - Background and aim: Flow cytometry (FCM) analysis of cerebrospinal fluid (CSF) is more sensitive than conventional cytology (CC) for diagnosis of lymphomatous meningeosis, but the clinical significance of occult central nervous system (CNS) disease (positive FCM with negative CC) remains unknown. Patients and methods: CSF samples from 105 patients with newly diagnosed aggressive lymphomas at high risk of CNS involvement were prospectively studied by both CC and FCM, and results were correlated with cumulative incidence of CNS relapse and overall survival (OS). Patients were divided into three groups: 1) patients without CNS involvement (CC-/FCM-; n = 83); 2) individuals with occult CNS disease (FCM+/CC-; n = 15); and 3) cases with CNS disease (CC+/FCM+; n = 7). Results: Six cases showed CNS relapse or progression: two in Group 1 (2.4%), two in Group 2 (13%) and two in Group 3 (28.5%) (Group 2 vs. 1, P = 0.04; Group 3 vs. 1, P < 0.001). Patients from Groups 2 (P = 0.05) and 3 (P < 0.001) also showed a higher cumulative incidence of CNS relapse than those from Group 1. Significant differences were observed in OS between FCM-/CC- and FCM+/CC+ cases (P = 0.02), while patients with occult CNS disease (FCM+/CC-) displayed intermediate OS rates, although differences did not reach statistical significance. Conclusions: The presence of occult CNS involvement at diagnosis in patients with NHL at high risk of CNS disease is associated with a higher probability of CNS relapse.
KW - central nervous system
KW - cerebrospinal fluid
KW - flow cytometry
KW - intrathecal
KW - non-Hodgkin's lymphoma
KW - relapse
UR - http://www.scopus.com/inward/record.url?scp=77956971692&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0609.2010.01478.x
DO - 10.1111/j.1600-0609.2010.01478.x
M3 - Article
C2 - 20528905
AN - SCOPUS:77956971692
SN - 0902-4441
VL - 85
SP - 321
EP - 328
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 4
ER -